Chemical messengers that transmit signals across synapses between neurons, or from neurons to target cells (muscle, gland, immune). Synthesized within neurons, packaged into synaptic vesicles, and released into the synaptic cleft via Calcium-dependent exocytosis in response to action potentials. They bind to postsynaptic receptors—ionotropic (ligand-gated ion channels for millisecond-scale responses) or metabotropic (G-protein coupled receptors for slower, amplified signaling)—and are then cleared by reuptake transporters, enzymatic degradation, or diffusion.
Imagine a postal system in a city where messages are delivered by chemical couriers. Each neuron is a post office. When an electrical signal (the postman's truck) arrives at the shipping dock (presynaptic terminal), calcium ions unlock the warehouse doors, and thousands of envelopes (neurotransmitters) are dumped into the street (synaptic cleft). Across the street, the receiving building (postsynaptic cell) has mailboxes (receptors) in two flavors: some are automatic doors that swing open instantly when the right letter arrives (ionotropic receptors—fast), while others trigger a whole chain of events inside the building—calling meetings, activating machinery, changing production schedules (metabotropic receptors—slow, amplified). After delivery, street cleaners (reuptake transporters like SERT) vacuum up leftover letters, or enzymes shred them on the spot (e.g., acetylcholinesterase), so the street is clean and ready for the next batch. But here's the clinical twist: when inflammatory cytokines flood this city—say, during chronic infection or chronic stress—they sabotage the courier system. They block envelope production (by shunting Tryptophan away from Serotonin via IDO), they damage the mailboxes, they make the street cleaners overactive (excessive reuptake), and they even burn some of the letters mid-flight. The result? Mail doesn't get delivered. Messages of reward (dopamine), calm (GABA), mood (Serotonin), and energy (norepinephrine) fail to arrive—and you get Depression, fatigue, cognitive dysfunction, and chronic pain.
¶ Synthesis and Packaging
Neurotransmitters are synthesized in neurons from precursors:
- Serotonin: Tryptophan → 5-hydroxytryptophan (5-HTP) via tryptophan hydroxylase → serotonin via aromatic L-amino acid decarboxylase
- Dopamine: Tyrosine → L-DOPA via tyrosine hydroxylase → dopamine via aromatic L-amino acid decarboxylase
- Norepinephrine: dopamine → norepinephrine via dopamine β-hydroxylase
- Acetylcholine: Choline + acetyl-CoA → acetylcholine via choline acetyltransferase
- Glutamate: synthesized from Glucose via transamination of 2-Oxoglutarate (α-ketoglutarate)
- GABA: glutamate → GABA via glutamic acid decarboxylase (GAD65/GAD67)
Synthesized neurotransmitters are packaged into synaptic vesicles by vesicular transporters (e.g., VMAT for monoamines, VAChT for acetylcholine, VGLUT for glutamate).
- Action potential arrives at presynaptic terminal
- Depolarization opens voltage-gated Calcium channels (Cav2.1, Cav2.2)
- Ca²⁺ influx triggers SNARE complex proteins (synaptobrevin, syntaxin, SNAP-25) to fuse vesicles with presynaptic membrane
- Exocytosis: neurotransmitter released into synaptic cleft
-
Ionotropic receptors (fast, 1-5 ms):
-
Metabotropic receptors (slow, 100 ms – minutes):
- G-protein coupled receptors (GPCRs): D1-D5 (dopamine), 5-HT1-7 (serotonin), muscarinic (acetylcholine), adrenergic (norepinephrine), mGluR1-8 (glutamate), GABA-B (GABA)
- Activate intracellular cascades: PKA, PKC, Akt pathway, ERK1/2
- Modulate gene transcription (CREB), receptor trafficking, synaptic structure
- Reuptake: transporters (SERT, DAT, NET, EAAT, GAT) pump neurotransmitter back into presynaptic neuron or glia
- Enzymatic degradation:
- Diffusion: out of synaptic cleft into extracellular space
inflammatory cytokines (TNF, IL-1β, IL-6, IFN-γ) disrupt neurotransmitter systems via:
- IDO activation by IFN-γ: shunts Tryptophan from Serotonin synthesis into kynurenine pathway, producing 3-Hydroxykynurenine and quinolinic acid (NMDA agonist, neurotoxic)
- TDO upregulation: cortisol-induced, same effect
- Tetrahydrobiopterin (BH4) depletion: Reactive Oxygen Species oxidize BH4, cofactor for tyrosine hydroxylase (dopamine synthesis) and tryptophan hydroxylase (serotonin synthesis) → reduced monoamine production
- Increased reuptake transporter expression: inflammatory cytokines upregulate SERT and DAT → excessive clearance → reduced synaptic availability
- Dopamine receptor downregulation: TNF-α reduces D1/D2 receptor density in basal ganglia
- glutamate excitotoxicity: microglia release excess glutamate; impaired astrocytic glutamate reuptake (EAAT2/GLT-1) → excitotoxicity
graph TD
A[Action Potential] --> B["Ca²⁺ Influx"]
B --> C[SNARE Complex Activation]
C --> D[Vesicle Fusion & Exocytosis]
D --> E[Neurotransmitter in Cleft]
E --> F[Ionotropic Receptor]
E --> G[Metabotropic Receptor]
F --> H["Ion Flux → Fast Potential Change"]
G --> I[G-Protein Activation]
I --> J[PKA/PKC/ERK Cascade]
J --> K[Gene Transcription CREB]
E --> L[Reuptake Transporter]
E --> M[Enzymatic Degradation]
L --> N[Neurotransmitter Recycled]
M --> N
O[Inflammatory Cytokines] --> P[IDO Activation]
P --> Q["Tryptophan → Kynurenine"]
Q --> R["↓ Serotonin Synthesis"]
O --> S[BH4 Oxidation]
S --> T["↓ Dopamine Synthesis"]
O --> U["↑ Reuptake Transporters"]
U --> V["↓ Synaptic Availability"]
O --> W["↓ Receptor Density"]
W --> X[Impaired Signaling]
Neurotransmitter disruption is a central mechanism linking inflammation to behavioral and cognitive symptoms in cPNI. The brain-immune axis operates bidirectionally: cytokines from systemic inflammation (gut, adipose, immune activation) cross the blood-brain barrier or signal via circumventricular organs and vagus nerve, activating microglia and disrupting neurotransmitter metabolism. This explains why patients with chronic inflammation—from IBD, rheumatoid arthritis, obesity, chronic infections, or chronic stress—present with Depression, anxiety, fatigue, and cognitive dysfunction.
- Depression: reduced Serotonin, Dopamine, norepinephrine due to IDO-mediated Tryptophan depletion, BH4 oxidation, increased reuptake. Classic SSRI resistance in inflammatory depression (CRP as depression biomarker >3 mg/L predicts poor SSRI response).
- chronic fatigue syndrome: dopaminergic dysfunction in basal ganglia and ventral striatum → reduced motivation, motor slowing, anhedonia. inflammation impairs reward system.
- cognitive dysfunction: glutamate excitotoxicity, reduced BDNF (modulated by serotonin), hippocampal neuroinflammation → impaired memory consolidation, executive function.
- chronic pain: imbalance of glutamate (excitatory) and GABA (inhibitory) in dorsal horn, descending pain facilitation from reduced serotonin/norepinephrine in dorsal raphe nucleus and locus coeruleus.
- Anxiety: GABAergic dysfunction, excessive glutamatergic signaling, dysregulated norepinephrine in amygdala and prefrontal cortex.
- Metamodel 5 (Chronic Life Stress): chronic cortisol → TDO activation → Tryptophan depletion → mood/anxiety disorders
- Metamodel 3 (Evolutionary Mismatch): modern diet low in omega-3 → reduced DHA → impaired membrane fluidity and receptor function; sedentary behavior → reduced BDNF → impaired neuroplasticity
- Selfish Brain: brain prioritizes Glucose and neurotransmitter precursors under metabolic stress; chronic stress "selfishly" diverts resources, impairing peripheral systems
¶ Biomarkers and Thresholds
- CRP >3 mg/L: predicts inflammatory depression, SSRI resistance
- IL-6 >10 pg/mL: associated with depressive symptoms, fatigue
- Kynurenine/Tryptophan ratio >0.05: indicates IDO activation, predicts mood dysfunction
- HbA1c >5.7%: insulin resistance impairs dopamine signaling
- Homocysteine >12 μmol/L: indicates B-vitamins deficiency (B6, B12, folate), impairs neurotransmitter synthesis
- Anti-inflammatory protocols: reduce systemic inflammation (gut healing, omega-3, exercise, sleep) → restore neurotransmitter synthesis
- Precursor support: Tryptophan, 5-HTP, Tyrosine, Choline, Amino Acids—but only effective if inflammation controlled
- Cofactor optimization: BH4 (via folate, vitamin C), vitamin B6 (cofactor for aromatic L-amino acid decarboxylase), B12, Zinc, Magnesium
- Microbiome modulation: gut microbiome produces neurotransmitter precursors (Tryptophan, GABA, short-chain fatty acids that modulate serotonin via enterochromaffin cells)
- Exercise: increases BDNF, restores dopaminergic signaling, enhances serotonin receptor sensitivity
- Reframe pharmacology: SSRIs/SNRIs work by blocking reuptake, but if synthesis is impaired (via inflammation), efficacy is limited—address root cause
- Major classes: Amino Acids (glutamate, GABA, glycine), monoamines (Dopamine, Serotonin, norepinephrine), Acetylcholine, Neuropeptides (substance P, enkephalins, oxytocin)
- Synaptic transmission speed: ionotropic 1-5 ms; metabotropic 100 ms – minutes
- inflammatory cytokines disrupt synthesis: IDO activation by IFN-γ diverts Tryptophan from Serotonin to kynurenine pathway, reducing serotonin by 50-70% in inflammatory states
- BH4 depletion: Reactive Oxygen Species from inflammation oxidize tetrahydrobiopterin, cofactor for tyrosine hydroxylase and tryptophan hydroxylase → reduced Dopamine and Serotonin synthesis
- Dopamine in motivation: basal ganglia dopamine signaling encodes effort-reward calculations; inflammation impairs this → anhedonia, psychomotor slowing, fatigue
- glutamate-GABA balance: excitatory/inhibitory ratio dysregulated in chronic pain, anxiety, epilepsy, neuroinflammation
- gut microbiome contribution: 90% of body's Serotonin produced in gut enterochromaffin cells; SCFAs (butyrate, propionate) modulate serotonin synthesis and release
- Reuptake transporter polymorphisms: 5-HTTLPR short allele (serotonin transporter) associated with increased stress sensitivity, depression risk
- COMT Val158Met polymorphism: Val/Val genotype → faster dopamine degradation → lower prefrontal dopamine, impaired executive function under stress
- Exam-relevant numbers: CRP >3 mg/L predicts SSRI non-response; kynurenine/tryptophan ratio >0.05 indicates inflammatory activation; IL-6 >10 pg/mL correlates with depressive symptoms
- neurons — synthesize, store, and release neurotransmitters; neuronal health depends on metabolic and immune homeostasis
- synaptic plasticity — neurotransmitter receptor activity and release probability underlie Long-Term Potentiation (LTP) and learning
- cytokines — inflammatory cytokines (TNF, IL-1β, IL-6, IFN-γ) disrupt neurotransmitter synthesis, reuptake, and receptor signaling
- dopamine — monoamine neurotransmitter critical for motivation, reward, motor control; primary target of inflammation in basal ganglia
- serotonin — monoamine neurotransmitter regulating mood, sleep, appetite; synthesis blocked by IDO-mediated Tryptophan depletion
- glutamate — primary excitatory neurotransmitter; excess release from microglia causes excitotoxicity in neuroinflammation
- GABA — primary inhibitory neurotransmitter; GABAergic dysfunction underlies anxiety, seizures, chronic pain sensitization
- norepinephrine — catecholamine modulating arousal, attention, stress response; synthesized in locus coeruleus; impaired in inflammatory fatigue
- Acetylcholine — neurotransmitter at neuromuscular junction and in Autonomic nervous system; critical for cholinergic anti-inflammatory pathway
- inflammation — systemic and neuroinflammation disrupt neurotransmitter systems, causing Depression, fatigue, cognitive dysfunction
- Depression — altered neurotransmitter function (serotonin, dopamine, norepinephrine) is central; inflammatory depression driven by IDO activation
- gut microbiome — produces neurotransmitter precursors (Tryptophan, GABA), SCFAs that modulate serotonin; dysbiosis impairs neurotransmission
- kynurenine pathway — inflammatory activation diverts Tryptophan from Serotonin synthesis; produces neurotoxic quinolinic acid
- indoleamine 2,3-dioxygenase — enzyme activated by IFN-γ; depletes Tryptophan, reduces serotonin, generates kynurenine metabolites
- basal ganglia — dopaminergic circuits here modulate motivation, motor function; inflammation impairs dopamine signaling → anhedonia, fatigue
- neuroinflammation — microglial activation releases cytokines, glutamate, Reactive Oxygen Species → disrupts neurotransmitter metabolism and receptor function
- chronic fatigue — dopaminergic dysfunction in reward circuits, reduced norepinephrine, inflammation-induced neurotransmitter depletion
- cognitive dysfunction — impaired glutamate-GABA balance, reduced BDNF (serotonin-dependent), excitotoxicity, hippocampal dysfunction
- brain-immune axis — bidirectional communication; immune signals modulate neurotransmitter systems; neurotransmitters regulate immune responses
- Neuropeptides — class of neurotransmitters with slow, modulatory effects; includes substance P, enkephalins, oxytocin, CRH
- BDNF — neurotrophin modulated by serotonin and dopamine; critical for neuroplasticity, synaptic plasticity, neurogenesis
- Tryptophan — precursor for Serotonin; diverted into kynurenine pathway by IDO during inflammation
- Tyrosine — precursor for Dopamine, norepinephrine, Adrenaline; synthesis requires BH4 cofactor, depleted in inflammation
- chronic stress — elevates cortisol → activates TDO → depletes Tryptophan → reduces serotonin; chronic norepinephrine depletion → fatigue
- microglia — brain-resident immune cells; when activated by inflammation, release cytokines, glutamate, Reactive Oxygen Species → disrupt neurotransmission
- vagus nerve — afferent fibers transmit immune signals (cytokines, microbial metabolites) to brain; modulate neurotransmitter systems in brainstem
- circumventricular organs — brain regions lacking blood-brain barrier; allow cytokines direct access to CNS, influencing neurotransmitter circuits
- chronic pain syndromes — dysregulated glutamate-GABA balance in dorsal horn; impaired descending inhibition (serotonin, norepinephrine) from dorsal raphe nucleus
- SERT — serotonin reuptake transporter; upregulated by inflammatory cytokines → excessive clearance → reduced synaptic serotonin
- COMT — enzyme degrading catecholamines (dopamine, norepinephrine); genetic polymorphisms affect stress resilience, executive function
- ventral tegmental area — dopaminergic nucleus projecting to nucleus accumbens, prefrontal cortex; critical for reward, motivation; impaired by inflammation